AKNAD1 Inhibitors
AKNAD1 inhibitors encompass a range of compounds that indirectly impede the functional activity of AKNAD1 through various biochemical pathways. For example, Rapamycin serves as an mTOR inhibitor, which by curtailing mTOR's role in protein synthesis, may lead to an indirect reduction in AKNAD1 function given that mTOR oversees a broad spectrum of protein translation processes. Similarly, Staurosporine, a protein kinase inhibitor, could disrupt kinase-mediated pathways essential for AKNAD1's post-translational modifications. In essence, the disruption of these signaling pathways by Staurosporine could negatively impact AKNAD1's functionality. PI3K inhibitors such as LY 294002 and Wortmannin could attenuate the PI3K/Akt pathway, potentially leading to diminished AKNAD1 activity if it is downstream of PI3K/Akt signaling. Kinase inhibitors like PD 98059 and U0126 target MEK, impinging on the MAPK/ERK pathway, which could reduce phosphorylation events necessary for AKNAD1's activity. SB 203580's inhibition of p38 MAPK could also disrupt AKNAD1 function if it is involved in stress and cytokine response pathways.
The JNK pathway, targeted by SP600125, is another signaling cascade whose inhibition could affect regulatory proteins that control AKNAD1's expression and function. Multi-targeted inhibitors such as Sunitinib and Sorafenib, which inhibit receptor tyrosine kinases, could suppress downstream signaling pathways that govern AKNAD1's activity. Lapatinib, a dual inhibitor of EGFR and HER2/neu, may reduce AKNAD1 activity by obstructing the pathways mediated by these receptors. Lastly, Bortezomib, by inhibiting the proteasome, can prevent the degradation of proteins that negatively regulate AKNAD1, thereby causing an accumulation that could diminish AKNAD1's functional activity. Collectively, these inhibitors, by affecting various signaling molecules and pathways, may lead to an overall decrease in AKNAD1 activity without directly altering its expression or requiring direct inhibition of the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, Rapamycin can lead to the downregulation of downstream protein synthesis, including the potential decrease in the functional activity of AKNAD1, as mTOR is involved in the translational control of a broad repertoire of proteins. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Although it is broad-spectrum, it can inhibit kinase-mediated signaling pathways that may be necessary for the post-translational modification or proper functioning of AKNAD1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that can diminish PI3K/Akt signaling. As this pathway is crucial for various cellular processes including survival and protein synthesis, inhibition of PI3K could lead to a reduction in AKNAD1 activity if AKNAD1 is downstream of PI3K/Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that can interfere with the MAPK/ERK pathway. This pathway's inhibition may lead to decreased phosphorylation events that could be required for AKNAD1 activity, thereby diminishing its functional role in the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can disrupt cellular responses to stress and cytokines, potentially leading to diminished AKNAD1 functionality if AKNAD1 is implicated in these responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can attenuate the PI3K/Akt pathway. Its inhibition can lead to a general decrease in protein synthesis and function, potentially impacting AKNAD1 activity indirectly. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway. By inhibiting JNK, it could affect transcription factors and other signaling molecules that regulate the expression and function of proteins, including potentially AKNAD1. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor. By inhibiting RTKs, it can impede the signaling pathways they mediate, such as the PI3K/Akt and MAPK pathways, which could indirectly lead to decreased AKNAD1 activity if AKNAD1 is a downstream effector. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2/neu. The inhibition of these receptors can lead to reduced activity of downstream pathways, including those that may regulate AKNAD1 function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that can inhibit several receptor tyrosine kinases and downstream signaling pathways, potentially leading to reduced AKNAD1 activity if it is involved in any of these pathways. | ||||||